Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 2/2012

01-03-2012

Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials

Authors: Dennis A. Revicki, Donald Stull, Margaret Vernon, Michael Rader, Dianne Tomita, Hema N. Viswanathan

Published in: Quality of Life Research | Issue 2/2012

Login to get access

Abstract

Purpose

This analysis examined the effects of darbepoetin alfa on hemoglobin and fatigue outcomes in patients with cancer using latent growth curve modeling (LGM).

Methods

Data from 4 clinical trials of darbepoetin alfa in lung cancer (2 studies; n = 547; n = 288), lymphoproliferative malignancies (n = 339), and non-myeloid malignancies (n = 320) were analyzed separately. Fatigue was assessed using the FACT-Fatigue (FACT-F) scale. Effects of darbepoetin alfa on changes in hemoglobin and FACT-F scores were evaluated using LGM, controlling for age, gender, Eastern Cooperative Oncology Group performance status, health status, and total transfusions.

Results

Patients receiving darbepoetin alfa had higher rates of change in hemoglobin (standardized regression coefficient [\( \hat{\beta } \)] = 0.30 to 0.53, all P < 0.05) than placebo. Patients with greater rates of change in hemoglobin reported improvements in fatigue outcomes (\( \hat{\beta } \) = 0.28 to 0.59, all P < 0.05). The total standardized effect of darbepoetin alfa on fatigue outcomes corresponded to a mean change of 0.9 to 3.5 points in FACT-F scores, with one trial demonstrating changes exceeding the minimal important difference of 3 points.

Conclusions

Darbepoetin alfa improved hemoglobin which was associated with improved fatigue across the 4 trials. Clinically, meaningful improvement in fatigue was seen in 2 trials. More complex statistical analysis models of treatment may assist in understanding the effects of erythropoiesis-stimulating agents on patient-reported outcomes.
Literature
1.
Ashbury, F. D., Findlay, H., Reynolds, B., & McKerracher, K. (1998). A Canadian survey of cancer patients’ experiences: Are their needs being met? Journal of Pain and Symptom Management, 16(5), 298–306.PubMedCrossRef
2.
Cella, D., Davis, K., Breitbart, W., & Curt, G. (2001). Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. Journal of Clinical Oncology, 19(14), 3385–3391.PubMed
3.
Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Annals of Oncology, 15(6), 979–986.PubMedCrossRef
4.
Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. Oncologist, 5(5), 353–360.PubMedCrossRef
5.
Irvine, D., Vincent, L., Graydon, J. E., Bubela, N., & Thompson, L. (1994). The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nursing, 17(5), 367–378.PubMedCrossRef
6.
Stone, P., Richards, M., A’Hern, R., & Hardy, J. (2000). A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Annals of Oncology, 11(5), 561–567.PubMedCrossRef
7.
Cella, D., Dobrez, D., & Glaspy, J. (2003). Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Annals of Oncology, 14(4), 511–519.PubMedCrossRef
8.
Chang, J., Couture, F., Young, S., McWatters, K. L., & Lau, C. Y. (2005). Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2597–2605.PubMedCrossRef
9.
Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P. Y., Demetri, G. D., Sarokhan, B. J., et al. (2002). Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95(4), 888–895.PubMedCrossRef
10.
Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875–2882.PubMed
11.
Gabrilove, J. L., Perez, E. A., Tomita, D. K., Rossi, G., & Cleeland, C. S. (2007). Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 micro g every 2 weeks. Cancer, 110(7), 1629–1640.PubMedCrossRef
12.
Glaspy, J. A., Jadeja, J. S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., et al. (2002). Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87(3), 268–276.PubMedCrossRef
13.
Johansson, J. E., Wersall, P., Brandberg, Y., Andersson, S. O., & Nordstrom, L. (2001). Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer—a randomized study. Scandinavian Journal of Urology and Nephrology, 35(4), 288–294.PubMedCrossRef
14.
Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T., & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117–124.
15.
Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865–2874.PubMed
16.
Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., et al. (2002). Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. Journal of Clinical Oncology, 20(10), 2486–2494.PubMedCrossRef
17.
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., et al. (2008). Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology, 26(1), 132–149.PubMedCrossRef
18.
Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A. B., et al. (2003). Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39(14), 2026–2034.PubMedCrossRef
19.
Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394–403.CrossRef
20.
Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317–325.PubMedCrossRef
21.
Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342–2349.PubMedCrossRef
22.
Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211–1220.PubMedCrossRef
23.
Minton, O., Stone, P., Richardson, A., Sharpe, M., & Hotopf, M. (2008). Drug therapy for the management of cancer related fatigue. Cochrane Database System Review, (1), CD006704.
24.
Ross, S. D., Allen, I. E., Henry, D. H., Seaman, C., Sercus, B., & Goodnough, L. T. (2006). Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clinical Therapy, 28(6), 801–831.CrossRef
25.
Bollen, K., & Curran, P. (2006). Latent curve models: A structural equation perspective. Hoboken, NJ: Wiley.
26.
Duncan, T., Duncan, S., & Strycker, L. (2006). An introduction to latent variable growth curve modeling: Concepts, issues, and applications. Mahwah, NJ: Lawrence Erlbaum Associates.
27.
Kline, R. B. (2010). Principles and practice of structural equation modeling. New York: Guilford Press.
28.
Stull, D. E. (2008). Analyzing growth and change: Latent variable growth curve modeling with an application to clinical trials. Quality of Life Research, 17(1), 47–59.PubMedCrossRef
29.
Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.PubMedCrossRef
30.
Cella, D. (1997). The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology, 34(3 Suppl 2), 13–19.PubMed
31.
Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24(6), 547–561.PubMedCrossRef
32.
Wothke, W. (2000). Longitudinal and multi-group modeling with missing data. In T. D. Little, K. Schnabel, & J. Baumert (Eds.), Modeling longitudinal and multilevel data: Practical issues, applied approaches, and specific examples. Mahwah, NJ: Lawrence Erlbaum Associates.
33.
Muthén, L. K., & Muthén, B. O. (1998–2007). Mplus user’s guide. Los Angeles, CA: Muthén & Muthén.
34.
Browne, M., & Cudeck, R. (1993). Alternative ways of assessing model fit. In K. Bollen & J. Long (Eds.), Testing structural equation models (pp. 136–162). Newbury Park, CA: Sage.
35.
Marsh, H. W., Hau, K. T., & Wen, Z. (2004). In search of golden rules: comment on hypothesis-testing approaches to setting cutoff values for fit indexes and dangers of overgeneralizing Hu and Bentler’s (1999) findings. Structural Equation Modeling, 11, 320–341.CrossRef
36.
Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102–109.PubMedCrossRef
Metadata
Title
Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials
Authors
Dennis A. Revicki
Donald Stull
Margaret Vernon
Michael Rader
Dianne Tomita
Hema N. Viswanathan
Publication date
01-03-2012
Publisher
Springer Netherlands
Published in
Quality of Life Research / Issue 2/2012
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-9946-z

Other articles of this Issue 2/2012

Quality of Life Research 2/2012 Go to the issue

OriginalPaper

Patient education methods to support quality of life and functional ability among patients with schizophrenia: a randomised clinical trial

OriginalPaper

The psychosocial impact of cancer: evidence in support of independent general positive and negative components

OriginalPaper

Health-related quality of life in breast cancer survivors of different sexual orientations

Brief Communication

Verification of the psychometric properties of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 palliative (EORTCQLQ-C15-PAL)

OriginalPaper

Rasch analysis in the development of a simplified version of the national eye institute visual-function questionnaire-25 for utility estimation

OriginalPaper

Differences in quality of life of hemodialysis patients between dialysis centers